Avadel Pharmaceuticals PLC 8-K filings
Avadel Pharmaceuticals announced a significant increase in revenue for the second quarter of 2024, primarily driven by the sales of its narcolepsy drug, LUMRYZ.
Avadel Pharmaceuticals successfully held its 2024 Annual Meeting of Shareholders, electing all nominated directors and ratifying the appointment of Deloitte & Touche LLP as the company's auditor.
Avadel Pharmaceuticals has dosed the first patient in its Phase 3 REVITALYZ trial, evaluating LUMRYZ for the treatment of idiopathic hypersomnia.
Avadel Pharmaceuticals will join the Russell 3000 Index effective July 1, 2024, enhancing its visibility among investors.
Avadel Pharmaceuticals has appointed Dr. Naseem Amin to its Board of Directors, effective May 17, 2024.
Avadel Pharmaceuticals has entered into a new sales agreement with Jefferies LLC to potentially sell up to $100 million of its ordinary shares through an at-the-market offering program.
Avadel Pharmaceuticals announced a strong first quarter of 2024, highlighted by $27.2 million in net revenue from LUMRYZ sales and significant patient enrollment growth.
Avadel Pharmaceuticals has completed a mandatory exchange of its American Depositary Shares (ADSs) for ordinary shares, resulting in a direct listing on the Nasdaq Stock Market.
Avadel Pharmaceuticals received a mixed jury verdict in a patent dispute with Jazz Pharmaceuticals, winning on one patent claim but losing on another, and plans to appeal the unfavorable decision.
8-K: Avadel Pharmaceuticals Reports $19.5 Million in Q4 LUMRYZ Revenue, Pediatric sNDA Target Date Set
Avadel Pharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighted by $19.5 million in net revenue from LUMRYZ sales in Q4 and a target FDA action date for its pediatric sNDA.